Ocular manifestations of systemic disease: Antineutrophil cytoplasmic antibody-associated vasculitis

Current Opinion in Ophthalmology

Volumn 22, Issue 6, 2011, Pages 489-495

  Schmidt, Jean ^a,b,c   Pulido, Jose S ^b   Matteson, Eric L ^a,b  

^a Division of Rheumatology   (United States)

^b MAYO CLINIC   (United States)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

antineutrophil cytoplasmic antibody associated vasculitis; Churg Strauss vasculitis; eye disease; granulomatosis with polyangiitis; treatment

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB;

CHURG STRAUSS SYNDROME; CLINICAL TRIAL; EYE DISEASE; GRANULOMATOUS VASCULITIS; HUMAN; KERATITIS; MICROSCOPIC POLYANGIITIS; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PSEUDOTUMOR; RETINITIS; REVIEW; SCLERITIS; SYSTEMIC DISEASE; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; EYE DISEASES; HUMANS;

EID: 80054933608     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32834bdfe2     Document Type: Review

References (51)

1. Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863-864.
2. Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clin North Am 2010; 36:545-558.
3. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192. (Pubitemid 24065492)
4. Baldini C, Talarico R, Della Rossa A, Bombardieri S. Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am 2010; 36:527-543.
5. Frankel SK, Jayne D. The pulmonary vasculitides. Clin Chest Med 2010; 31:519-536.
6. Holle JU, Laudien M, Gross WL. Clinical manifestations and treatment of Wegener's granulomatosis. Rheum Dis Clin North Am 2010; 36:507-526.
7. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117:39-50. (Pubitemid 38798019)
8. Mohan N, Kerr GS. ANCA-associated small vessel vasculitis: clinical and therapeutic advances. Curr Rheumatol Rep 2010; 12:406-413.
9. Basu N, Watts R, Bajema I, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010; 69:1744-1750.
10. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1101-1107. (Pubitemid 20273294)
11. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094-1100. (Pubitemid 20273293)
12. Chen M, Kallenberg CG. The environment, geoepidemiology and ANCAassociated vasculitides. Autoimmun Rev 2010; 9:A293-A298.
13. Kallenberg CG. Pathogenesis of ANCA-associated vasculitis, an update. Clin Rev Allergy Immunol 2011. [Epub ahead of print]
14. Silva F, Hummel AM, Jenne DE, Specks U. Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen. J Autoimmun 2010; 35:299-308.
15. Mahr AD, Edberg JC, Stone JH, et al. Alpha-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis Rheum 2010; 62:3760-3767.
16. Tadema H, Abdulahad WH, Lepse N, et al. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology (Oxford) 2011; 50:689-696.
17. Bibby S, Healy B, Steele R, et al. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010; 65:132-138.
18. Langford CA. Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Immunol 2011; 164 (Suppl 1):31-34.
19. Turnbull J, Harper L. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 2009; 23:391-401.
20. Le Guenno G, Mahr A, Pagnoux C, et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011.
21. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
22. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
23. Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011. [Epub ahead of print]
24. Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement: a prospective, open-label pilot trial. Clin J Am Soc Nephrol 2010; 5:445-453.
25. MYCYC.http://www.vasculitis.org/images/documents/mycyc%20newsletter %2022.10.2010.pdf. [Accessed 14 April 2011]
26. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310-317.
27. Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011; 57:566-574.
28. PEXIVAS. http://www.bctu.bham.ac.uk/pexivas/index.shtml. [Accessed 14 April 2011]
29. Casian A, Jayne D. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr Opin Rheumatol 2011; 23:12-17.
30. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304:2381-2388.
31. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 2010; 62:1166-1173.
32. Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90:19-27.
33. Ribi C, Cohen P, Pagnoux C, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 2010; 62:1186-1197.
34. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461-2469. (Pubitemid 41117433)
35. Wolter NE, Ooi EH, Witterick IJ. Intralesional corticosteroid injection and dilatation provides effective management of subglottic stenosis in Wegener's granulomatosis. Laryngoscope 2010; 120:2452-2455.
36. Moosig F, Holle JU, Gross WL. Value of antiinfective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther 2009; 11:253.
37. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis. Arthritis Care Res 2010; 62:1515-1526.
38. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCAassociated vasculitis. Ann Rheum Dis 2011; 70:488-494.
39. Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011; 63:257-266.
40. Suppiah R, Robson J, Luqmani R. Outcome measures in ANCA-associated vasculitis. Rheum Dis Clin North Am 2010; 36:587-607.
41. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68:1827-1832.
42. Suppiah R, Flossman O, Mukhtyar C, et al. Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann Rheum Dis 2011; 70:80-85.
43. Pulido JS, Goeken JA, Nerad JA, et al. Ocular manifestations of patients with circulating antineutrophil cytoplasmic antibodies. Arch Ophthalmol 1990; 108:845-850. (Pubitemid 20193845)
44. Fechner FP, Faquin WC, Pilch BZ. Wegener's granulomatosis of the orbit: a clinicopathological study of 15 patients. Laryngoscope 2002; 112:1945-1950. (Pubitemid 35283453)
45. Plaza JA, Garrity JA, Dogan A, et al. Orbital inflammation with IgG4-positive plasma cells: manifestation of IgG4 systemic disease. Arch Ophthalmol 2011; 129:421-428.
46. Levy-Clarke G, Ding X, Gangaputra S, et al. Recalcitrant granulomatous sclerouveitis in a patient with granulomatous ANCA-associated vasculitis. Ocul Immunol Inflamm 2009; 17:83-87.
47. Proia AD. Granulomatous choroiditis in Wegener granulomatosis. Arch Ophthalmol 2011; 129:520-521.
48. Iida T, Spaide RF, Kantor J. Retinal and choroidal arterial occlusion in Wegener's granulomatosis. Am J Ophthalmol 2002; 133:151-152. (Pubitemid 34076521)
49. Caster JC, Shetlar DJ, Pappolla MA, Yee RW. Microscopic polyangiitis with ocular involvement. Arch Ophthalmol 1996; 114:346-348. (Pubitemid 26086743)
50. Mihara M, Hayasaka S, Watanabe K, et al. Ocular manifestations in patients with microscopic polyangiitis. Eur J Ophthalmol 2005; 15:138-142. (Pubitemid 40462745)
51. Hara A, Ohta S, Takata M, et al. Microscopic polyangiitis with ocular manifestations as the initial presenting sign. Am J Med Sci 2007; 334:308-310. (Pubitemid 351339292)